Is this the Future of Medical Affairs?

States look to require Medical Affairs/MSL professionals to become BCMAS credentialed. Read More as reported in Forbes

forbes_logo

ACMA in the News

The Standard in Pharmaceutical Industry Training & Credentialing


Podcasts

Hands-On BCMAS: A Conversation with Dr. Jamie Dettler-Leonard

Posted: November 07, 2018

MSL Professional Jamie M. Dettler-Leonard, PhD, BCMAS from Johnson & Johnson discusses her experience with the BCMAS program on the Pharmacy Podcast Network.

Lifting Pharma Credibility and Trustworthiness With Certified Medical Affairs Teams, With Dr. William Soliman

Posted: June 28, 2018

Stacey_Richter

According to the Edelman survey on trust, 77% of people surveyed refused to purchase a product or service because they did not trust the company behind it. Pharma companies are not exactly tops on the trust scale for reasons you can infer yourself—or listen to EP148 with Jennifer Miller on the Good Pharma Scorecard. As with most…Read More

Breaking Down the BCMAS Certification: A Conversation with Dr. William Soliman of ACMA

Posted: June 21, 2018

BCMAS_Podcast

An experienced executive with several years of experience in the pharmaceutical and biotechnology industry, Dr. Soliman has held key positions within medical affairs where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry.

In the Press

Chicago Leads Battle Against Opioid Crisis

Posted: June, 2018

CMS-9-18-Publication

ACMA featured on page 19 as Accreditor working with drug reps and medical affairs professionals.

Accreditation Council for Medical Affairs Appoints Accera CEO, Dr. Charles Stacey to its Board of Governors

Posted: Sept 06, 2018

Charles-Stacey

The ACMA has appointed Dr. Charles Stacey, President and CEO of Accera Pharmaceuticals to its Board of Governors. Dr. Stacey is the President and CEO of Accera, a global clinical stage biotechnology company focused on the development of therapeutics for CNS disease. Prior to joining Accera, he was with Inventages, the Nestlé backed venture capital and private equity group, with $1.5Bn under management. There he led the CNS interest as well as the fund's interest in Asia. Prior to Inventages, Dr. Stacey ran a medical device company and worked for a number of early-stage healthcare companies.

Accreditation Council Appoints Pharma Power Players, former Otsuka CEO, Bob Oliver and Astellas Executive, S. Bob Chib to its Board of Governors

Posted: Aug 30, 2018

The ACMA has appointed two power players to its Board of Governors Bob Oliver and S. Bob Chib.

Bob Oliver

Bob Oliver, Recent CEO of V ClinBio, former President and CEO of Otsuka Pharmaceuticals, who also serves as Executive Advisor for both Cellix Bio Sciences Inc and Hyalo Technologies, while serving on the Board of Directors for Neurotez Inc., joins the ACMA Board today.

Bob Chib

S. Bob Chib, currently serves as the Head of Corporate Strategy, Innovation, and Business Development at Astellas Pharma. Mr. Chib has more than two decades' experience as a senior biopharma executive.

ACMA Partners with the Council for Continuing Pharmaceutical Education of Canada

Posted: July 10, 2018

The partnership between the ACMA and Council for Continuing Pharmaceutical Education (CCPE) will enable more medical affairs and MSL professionals in Canada to become Board Certified in Medical Affairs via the Board Certified Medical Affairs Specialist Program (BCMAS). The CCPE and ACMA have collaborated to put together a first in class training program tailored for Canadian MSL professionals.

ARTICLES

Why I Became a Board Certified Medical Affairs Specialist (BCMAS)

Posted: July 17, 2018

Imagine this scenario: a pharmacist makes a recommendation to a physician to either change, or add a medication to a patient’s regimen but the physician does not accept the recommendation since he or she is either unfamiliar with or does not have much experience with the drug and does not feel comfortable prescribing it. Medical affairs helps tear down these barriers so that both physicians and patients have access to scientifically accurate data and other information they need about a medication.....Read More